

No. BPPI/DRUG/RC-128/2020, No. BPPI/DRUG/RC-150/2020
No. BPPI/DRUG/RC-156/2020

Dated: 07/10/2021

ORDER

Bureau of Pharma Public Sector Undertakings of India, New Delhi now Pharmaceuticals & Medical Devices Bureau of India (PMBI) had published tender No. BPPI/DRUG/RC-128/2020, No. BPPI/DRUG/RC-150/2020, No. BPPI/DRUG/RC-156/2020 on date 11.02.2020, 04.04.2020 and 17.07.2020 through e-procurement system for supply of drugs for the year 2020-21, 2020-22.

Whereas M/S Medipol Pharmaceuticals India Pvt. Ltd. (here after called as the company) address at 128/5, Swiss House, Vishwas Nagar, Delhi-110032 has participated in tenders. The firm awarded letter of acceptance on date 07.04.2020, 09.04.2020 and 15.09.2020 for tender no. BPPI/DRUG/RC-128/2020 and 22.04.2020 and 28.08.2020 for tender No. BPPI/DRUG/RC-150/2020 and 14.12.2020, 27.01.2021, 26.02.2021 for tender no. BPPI/DRUG/RC-156/2020 for the period of 1 and 2 years as per tender provision.

Whereas, Pharmaceuticals & Medical Devices Bureau of India, New Delhi sent show cause notice vide reference No. BPPI/DRUG/RC-128/2020, No. BPPI/DRUG/RC-150/2020, No. BPPI/DRUG/RC-156/2020 to M/S Medipol Pharmaceuticals India Pvt. Ltd. through mail/DAK date 06.08.2021 asking for explanation to the firm informing about provisions of the clause no. 4(H), 13(C), 27(A), 31(B), 31(B) Sub-Clause (V) of tenders document with request to explain the concealing the fact about blacklisting of the firm by GMSD (Government Medical Store Depots/ Medical Store Organization, Directorate General of health Services, Government of India to PMBI while participating in above mentioned tenders.

As per reply against show cause notice clarification and statement seems to be vague and not at all satisfactory to PMBI. As per office memorandum vide reference no. PS/De-regn./Medipol/2020-21/2795 date 04.12.2020, M/S Medipol Pharmaceuticals India Pvt. Ltd. has been De-registered/Debarred for supply of all drugs/products to MSO/GMSDs for period of five (05) years w.e.f. 24.10.2021 to 24.10.2024.

In view of above, M/S Medipol Pharmaceuticals India Pvt. Ltd. is blacklisted for period of two (02) successive years to participate in the tender of **Pharmaceuticals & Medical Devices Bureau of India, New Delhi** for supply of all drugs/products from date of issuance of this order. Besides forfeiture of Performance Security from all supplied purchase orders against above mentioned tenders of Rs. 1645327/-

This order is without prejudice to the legal and criminal action to be taken if any, by Pharmaceuticals & Medical Devices Bureau of India, New Delhi in the matter.



Parth Gautam Sharma, IRS
Dy. Chief Executive Officer
Pharmaceuticals & Medical Devices Bureau of India, New Delhi

Regd.
To,
M/S Medipol Pharmaceuticals India Pvt. Ltd.
128/5, Swiss House,
Vishwas Nagar, Delhi-110032

E. & O. E